

厚生労働行政推進調査事業費補助金（肝炎等克服政策研究事業）
分担研究報告書

肝がん・重度肝硬変の治療に係るガイドラインの作成等に資する研究

工藤 正俊 近畿大学医学部 消化器内科 主任教授

データ収集プラットフォーム整備

A. 研究目的

肝癌に対する複合免疫療法の効果と安全性を検証すること。特に各国の研究状況と成績における実態調査を行う事。

B. 研究方法

肝癌に対する各種国際学会に出席し発表を行うとともに、海外のデータについても日本との成績と比較検討する。

C. 研究結果

日本の肝癌における複合免疫療法が海外とはアプローチ方法が異なり、最も優れる事が判明した。

D. 考察

今後日本において、肝癌の治療を効率的に進めるには高額な複合免疫療法の経済的サポートが重要と考えられた。

E. 結論

日本の肝癌の治療、特に複合免疫療法による治療成績は海外より優れていると考えられた。これに対して、極めて高額な医療費をサポートする仕組みは極めて重要であると考えられた。

F 健康危険情報 なし

G 研究発表

1.論文発表

1. Yau T, Park JW, Finn RS, Cheng AL, Mathurin P, Edeline J, Kudo M, Harding JJ, Merle P, Rosmorduc O, Wyrwicz L, Schott E, Choo SP, Kelley RK, Sieghart W, Assenat E, Zaucha R, Furuse J, Abou-Alfa GK, El-Khoueiry AB, Melero I, Begic D, Chen G, Neely J, Wisniewski T, Tschalka M, Sangro B: Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial. *Lancet Oncol* 23:77-90, 2022.
2. Aoki T, Nishida N, Kudo M: Current perspectives on the Immunosuppressive niche and role of fibrosis in hepatocellular carcinoma and the development of anti-tumor Immunity. *J Histochem Cytochem* 70:53-81, 2022.
3. Aoki T, Nishida N, Kudo M: Clinical significance of the duality of Wnt/ β -catenin signaling in human hepatocellular carcinoma. *Cancers* 14:444, 2022. doi: 10.3390/cancers14020444
4. Yamagishi S, Doman K, Mekada Y, Nishida N, Kudo M: Detection and tracking of liver tumors for ultrasound diagnostic support using deep learning. *Journal of Image and Graphics (JOIG)* 10:50-55, 2022. doi: 10.18178/joig.10.1.50-55

5. Kudo M: Newly developed modified ALBI grade shows better prognostic and predictive value for hepatocellular carcinoma. *Liver Cancer* 11:1-8, 2022.
6. Nishida N, Yamakawa M, Shiina T, Mekada Y, Nishida M, Sakamoto N, Nishimura T, Iijima H, Hirai T, Takahashi K, Sato M, Tateishi R, Ogawa M, Mori H, Kitano M, Toyoda H, Ogawa C, Kudo M, JSUM AI investigators: Artificial intelligence (AI) models for the ultrasonographic diagnosis of liver tumors and comparison of diagnostic accuracies between AI and human experts. *J Gastroenterol* 57:309-321, 2022.
7. Llovet JM, Vogel A, Madoff DC, Finn RS, Ogasawara S, Ren Z, Mody K, Li JJ, Siegel AB, Dubrovsky L, Kudo M: Randomized phase 3 LEAP-012 study: Transarterial chemoembolization with or without lenvatinib plus pembrolizumab for intermediate-stage hepatocellular carcinoma not amenable to curative treatment. *Cardiovasc Intervent Radiol (CVIR)* 45:405-412, 2022.
8. Cheng AL, Qin S, Ikeda M, Galle PR, Ducreux M, Kim TY, Lim HY, Kudo M, Breder V, Merle P, Kaseb A, Li D, Verret W, Ma N, Nicholas A, Wang Y, Li L, Zhu AX, Finn RS: Updated efficacy and safety data from IMbrave150: atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma. *J Hepatol* 76:862-873, 2022.
9. Kudo M, Izumi N, Kokudo N, Sakamoto M, Shiina S, Takayama T, Tateishi R, Nakashima O, Murakami T, Matsuyama Y, Takahashi A, Miyata H, Kubo S: Report of the 22nd nationwide follow-up survey of primary liver cancer in Japan (2012–2013). *Hepatol Res* 52:5-66, 2022.
10. Kudo M, Ikeda M, Ueshima K, Sakamoto M, Shiina S, Tateishi R, Nouse K, Hasegawa K, Furuse J, Miyayama S, Murakami T, Yamashita T, Kokudo N: Response evaluation criteria in cancer of the liver (version 6) (RECICL 2021 revised version). *Hepatol Res* 52:329-336, 2022.
11. Hiraoka A, Kumada T, Tada T, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H, Yasuda S, Toyoda H, Ogawa C, Nishimura T, Hatanaka T, Kakizaki S, Shimada N, Kawata K, Naganuma A, Tanaka T, Ohama H, Nouse K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Imai M, Koizumi Y, Nakamura S, Joko K, Iijima H, Hiasa Y, Kudo M: Early experience of atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma BCLC-B stage patients classified as beyond up to seven criteria -Multicenter analysis. *Hepatol Res* 52:308-316, 2022.
12. Hagiwara S, Nishida N, Ida H, Ueshima K, Minami Y, Takita M, Aoki T, Morita M, Chishina H, Komeda Y, Yoshida A, Park AM, Sato M, Kawada A, Nakano H, Nakagawa H, Kudo M: Role of phlebotomy in the treatment of liver damage related to erythropoietic porphyria. *Sci Rep* 12:6100, 2022.
13. Kudo M: Durvalumab plus tremelimumab: A novel combination Immunotherapy for unresectable hepatocellular carcinoma. *Liver Cancer* 11:87-93, 2022.
14. Minami Y, Takaki H, Yamakado K, Kudo M: How compatible are immune checkpoint inhibitors and thermal ablation for liver metastases? *Cancers* 14:2206, 2022. doi.org/10.3390
15. Chan HLY, Vogel A, Berg T, de Toni E, Kudo M, Trojan J, Weinmann A, Eiblmaier A, Klein HG, Hegel JK, Sharma A, Madin K, Rolny V,

- Lisy MR, Piratvisuth T: Performance evaluation of the Elecsys PIVKA-II and Elecsys AFP assays for hepatocellular carcinoma diagnosis. *JGH Open*:292-300, 2022. doi:10.1002/jgh3.12720
16. Abou-Alfa G[†], Lau G[†], Kudo M[†], Chan SL[†], Kelley RK, Furuse J, Sukeepaisarnjaroen W, Kang YK, Tu DV, De Toni E, Rimassa L, Breder V, Vasilyev A, Heurgue A, Tam V, Mody K, Thungappa SC, Ostapenko Y, Yau T, Azevedo S, Varela M, Cheng AL, Qin S, Galle P, Ali S, Marcovitz M, Makowsky M, Pharm D, He P, Kurland JF, Negro A, Sangro B: Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma. *New Engl J Med Evidence*, 2022. (†Shared 1st authors) DOI: 10.1056/EVIDoa2100070
 17. Chan SL, Schuler M, Kang YK, Yen CJ, Edeline J, Choo SP, Lin CC, Okusaka T, Weiss KH, Macarulla T, Cattani S, Blanc JF, Lee KH, Maur M, Pant S, Kudo M, Assenat E, Zhu AX, Yau T, Lim HY, Bruix J, Geier A, Guillen-Ponce C, Fasolo A, Finn RS, Fan J, Vogel A, Qin S, Riester M, Katsanou V, Chaudhari M, Kakizume T, Gu Y, Porta DG, Myers A, Myers A, Delord JP: A first-in-human phase 1/2 study of FGF401 and combination of FGF401 with spartalizumab in patients with hepatocellular carcinoma or Biomarker-selected solid tumors. *J Exp Clin Cancer Res* 41:189, 2022. <https://doi.org/10.1186/s13046-022-02383-5>
 18. Tanaka T, Hiraoka A, Tada T, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H, Yasuda S, Toyoda H, Ogawa C, Nishimura T, Hatanaka T, Kakizaki S, Shimada N, Kawata K, Naganuma A, Kosaka H, Ohama H, Nouse K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Imai M, Koizumi Y, Nakamura S, Joko K, Iijima H, Kaibori M, Hiasa Y, Kudo M, Kumada T: Therapeutic efficacy of atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma in patients with Child-Pugh class A or B liver function in real-world clinical practice. *Hepatol Res* 52: 773-783, 2022.
 19. Marinelli B, Kim E, D'Alessio A, Cedillo M, Sinha I, Debnath N, Pathel RS, Kudo M, Nishida N, Saeed A, Hildebrand H, Kaseb A, Abugabal Y, Pillai A, Huang YH, Khan U, Muzaffar M, Naqash AR, Fischman A, Bishay V, Bettinger D, Sung M, Ang C, Schwartz M, Pinato DJ, Marron TU: Integrated use of PD-1 inhibition and transarterial chemoembolization for hepatocellular carcinoma: evaluation of safety and efficacy in a retrospective, propensity score-matched study. *J ImmunoTher Cancer* 10:e004205, 2022. doi: 10.1136/jitc-2021-004205
 20. Kudo M: New treatment paradigm with systemic therapy in Intermediate-stage hepatocellular carcinoma. *Int J Clin Oncol* 27:1110-1119, 2022.
 21. Sharma R, Pillai A, Marron TU, Fessas P, Saeed A, Jun T, Dharmapuri S, Szafron D, Naqash AR, Gampa A, Wang Y, Khan U, Muzaffar M, Navaid M, Lee CJ, Lee PC, Bulumulle A, Yu B, Paul S, Nimkar N, Bettinger D, Hildebrand H, Abugabal YI, Pressiani T, Kaseb A, Huang YH, Ang C, Kudo M, Nishida N, Personeni N, Rimassa L, Pinato DJ: Patterns and outcomes of subsequent therapy after immune checkpoint inhibitor discontinuation in hepatocellular carcinoma. *Hepatol Commun* 6:1776-1785, 2022. doi.org/10.1002/hep4.1927
 22. Verset G, Borbath I, Karwal M, Verslype C, Van Vierberghe H, Kardosh A, Zagonel V, Stal P, Sarker D, Palmer D, Vogel A, Edeline J,

- Cattan S, Kudo M, Cheng AL, Ogasawara S, Daniele B, Chan S, Finn R, Knox J, Qin SK, Siegel A, Chisamore M, Hatogai K, Wang A, Zhu A: Pembrolizumab monotherapy for previously untreated advanced hepatocellular carcinoma: data from the open-label, phase 2 KEYNOTE-224 trial. *Clin Cancer Res* 28:2547-2554, 2022.
23. Kudo M, Finn RS, Edeline J, Cattan S, Ogasawara S, Palmer D, Verslype C, Zagonel V, Fartoux L, Vogel A, Sarker D, Verset G, Chan SL, Knox J, Daniele B, Yau T, Gurary EB, Siegel AB, Wang A, Cheng AL, Zhu AX, on behalf of the KEYNOTE-224 Investigators: Updated efficacy and safety of KEYNOTE-224: a phase 2 study of pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib. *Eur J Cancer* 167:1-12, 2022. doi: 10.1016/j.ejca.2022.02.009
 24. Llovet JM, Singal AG, Villanueva A, Finn RS, Kudo M, Galle PR, Ikeda M, Callies S, McGrath LM, Wang C, Abada P, Widau RC, Gonzalez-Gugel E, Zhu AX: Prognostic and predictive factors in patients with advanced HCC and elevated alpha-fetoprotein treated with ramucirumab in two randomized Phase III trials. *Clin Cancer Res* 28:2297-2305, 2022.
 25. Kudo M: Selection of systemic treatment regimen for unresectable hepatocellular carcinoma: Does etiology matter? *Liver Cancer* 11:283-289, 2022.
 26. Kudo M[†], Ueshima K[†], Ikeda M, Torimura T, Tanabe N, Aikata H, Izumi N, Yamasaki T, Nojiri S, Hino K, Tsumura H, Kuzuya T, Isoda N, Moriguchi M, Aino H, Ido A, Kawabe N, Nakao K, Wada Y, Ogasawara S, Yoshimura K, Okusaka T, Furuse J, Kokudo N, Okita K, Johnson P, Arai Y: Final results of TACTICS: A randomized, prospective trial comparing transarterial chemoembolization plus sorafenib to transarterial chemoembolization alone in patients with unresectable hepatocellular carcinoma. *Liver Cancer* 11:354-367, 2022. (†Shared 1st authors)
 27. Tada T, Kumada T, Hiraoka A, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H, Yasuda S, Toyoda H, Hatanaka T, Kakizaki S, Shimada N, Kawata K, Tanaka T, Ohma H, Nouse K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Imai M, Naganuma A, Aoki T, Koizumi Y, Nakamura S, Joko K, Hiasa Y, Kudo M: Glasgow prognostic score predicts survival in patients with unresectable hepatocellular carcinoma treated with lenvatinib: a multicenter analysis. *Eur J Gastroenterol Hepatol* 34:857-864, 2022.
 28. Okushin K, Tateishi R, Takahashi A, Uchino K, Nakagomi R, Nakatsuka T, Minami T, Sato M, Fujishiro M, Hasegawa K, Eguchi Y, Kanto T, Kubo S, Yoshiji H, Miyata H, Izumi N, Kudo M, Koike K: Current status of primary liver cancer and decompensated cirrhosis in Japan: Launch of a nationwide registry for advanced liver diseases (REAL). *J Gastroenterol* 57:587-597, 2022.
 29. Kudo M: Combination immunotherapy with anti-PD-1/PD-L1 antibody plus anti-VEGF antibody may promote cytotoxic T lymphocyte infiltration in hepatocellular carcinoma, including in the non-inflamed subclass. *Liver Cancer* 11:185-191, 2022.
 30. Okusaka T, Kudo M, Ikeda K, Ikeda M, Okita K, Sugawara M, Tamai T, Ren M, Saito K, Kumada H: Impact of bodyweight-based starting doses on the safety and efficacy of lenvatinib in primarily Japanese patients with hepatocellular carcinoma. *Hepatol Res*

- 52:784-793, 2022.
31. Kudo M: Durvalumab plus tremelimumab in unresectable hepatocellular carcinoma. *Hepatobil Surg Nutr* 11:592-596, 2022.
 32. Hagiwara S, Nishida N, Ida H, Ueshima K, Minami Y, Takita M, Aoki T, Morita M, Chishina H, Komeda Y, Yoshida A, Hayashi H, Nakagawa K, Kudo M: Clinical implication of immune checkpoint inhibitor on the chronic hepatitis B virus infection. *Hepatol Res* 52:754-761, 2022.
 33. Hagiwara S, Yoshida T, Nishida N, Ida H, Ueshima K, Minami Y, Takita M, Aoki T, Morita M, Chishina H, Komeda Y, Yoshida A, Hayashi H, Nakagawa K, Kudo M: Progression from early to advanced stage of immune-related cholangitis. *Hepatol Res* 52:888-892, 2022.
 34. Minami Y, Aoki T, Chishina H, Takita M, Hagiwara S, Ida H, Ueshima K, Nishida N, Kudo M: Prognostic factors for overall survival in patients with HCV-Related HCC undergoing molecular targeted therapies: beyond a sustained virological response. *Cancers* 14: 4850, 2022.
 35. Ueshima K, Komemushi A, Aramaki T, Iwamoto H, Obi S, Sato Y, Tanaka T, Matsueda K, Moriguchi M, Saito H, Sone M, Yamagami T, Inaba Y, Kudo M, Arai Y: Clinical practice guidelines for hepatic arterial infusion chemotherapy with a port system proposed by the Japanese Society of Interventional Radiology and Japanese Society of implantable port assisted treatment. *Liver Cancer* 11:407-425, 2022.
 36. Kudo M: Atezolizumab plus bevacizumab followed by curative conversion (ABC conversion) in patients with unresectable, TACE-unsuitable Intermediate-stage hepatocellular carcinoma. *Liver Cancer* 11:399-406, 2022.
 37. Fulgenzi CAM, Cheon J, D'Alessio A, Nishida N, Ang C, Marron TU, Wu L, Saeed A, Wietharn B, Cammarota A, Pressiani T, Personeni N, Pinter M, Scheiner B, Balcar L, Napolitano A, Huang YH, Phen S, Naqash AR, Vivaldi C, Salani F, Masi G, Bettinger D, Vogel A, Schönlein M, von Felden J, Schulze K, Wege H, Galle PR, Kudo M, Rimassa L, Singal AG, Sharma R, Cortellini A, Gaillard VE, Chon HJ, Pinato DJ: Reproducible safety and efficacy of atezolizumab plus bevacizumab for HCC in clinical practice: Results of the AB-real study. *Eur J Cancer* 175:204-213, 2022.
 38. Vithayathil M, D'Alessio A, Fulgenzi CAM, Nishida N, Schönlein M, von Felden J, Schulze K, Wege H, Saeed A, Wietharn B, Hildebrand H, Wu L, Ang C, Marron TU, Weinmann A, Galle PR, Bettinger D, Bengsch B, Vogel A, Balcar L, Scheiner B, Lee PC, Huang YH, Amara S, Muzaffar M, Naqash AR, Cammarota A, Personeni N, Pressiani T, Pinter M, Cortellini A, Kudo M, Rimassa L, Pinato DJ, Sharma R: Impact of older age in patients receiving atezolizumab and bevacizumab for hepatocellular carcinoma. *Liver Int* 42:2538-2547, 2022.
 39. Rimini M, Rimassa L, Ueshima K, Burgio V, Shigeo S, Tada T, Suda G, Yoo C, Cheon J, Pinato DJ, Lonardi S, Scartozzi M, Iavarone M, Di Costanzo GG, Marra F, Soldà C, Tamburini E, Piscaglia F, Masi G, Cabibbo G, Foschi FG, Silletta M, Pressiani T, Nishida N, Iwamoto H, Sakamoto N, Ryoo BY, Chon HJ, Claudia F, Niizeki T, Sho T, Kang B, D'Alessio A, Kumada T, Hiraoka A, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H, Yasuda S, Toyoda H, Ogawa C, Nishimur T, Hatanaka T, Kakizaki S,

- Shimada N, Kawata K, Tanaka T, Ohama H, Nouse K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Imai M, Naganuma A, Koizumi Y, Nakamura S, Joko K, Iijima H, Hiasa Y, Pedica F, De Cobelli F, Ratti F, Alrighetti L, Kudo M, Cascinu S, Casadei-Gardini A: Atezolizumab plus bevacizumab versus lenvatinib or sorafenib in non-viral unresectable hepatocellular carcinoma: an international propensity score matching analysis. *ESMO Open* 7:100591, 2022.
40. Hagiwara S, Komeda Y, Nishida N, Yoshida A, Kudo M: A case of HCC successfully treated with infliximab-steroid sequential therapy for small bowel perforation due to atezolizumab/bevacizumab combination therapy. *Cancer Rep* 5:e1721, 2022. doi: 10.1002/cnr2.1721
41. Rimini M, Kang W, Burgio V, Persano M, Aoki T, Shimose S, Tada T, Kumada T, Sho T, Lai E, Celsa C, Campani C, Tonnini M, Tamburini E, Hiraoka A, Takaguchi K, Nishida N, Iwamoto H, Itobayashi E, Tsuji K, Sakamoto N, Ishikawa T, Toyoda H, Kudo M, Kawaguchi T, Hatanaka T, Nouse K, Suda G, Cabibbo G, Marra F, Della Corte A, Ratti F, Pedica F, De Cobelli F, Alrighetti L, Scartozzi M, Cascinu S, Casadei-Gardini A: Validation of the easy-to-use Lenvatinib prognostic (LEP) index to predict prognosis in advanced hepatocellular carcinoma patients treated with Lenvatinib. *Hepatol Res* 52:1050-1059, 2022.
42. Kim SK, Fujii T, Kim SR, Lim YS, Hagiwara S, Kudo M: Hepatitis B virus treatment and hepatocellular carcinoma - controversies and approaches to consensus. *Liver Cancer* 11:497-510, 2022.
43. Kudo M: Implications of the TACTICS trial: Establishing the new concept of combination/sequential systemic therapy and TACE to achieve synergistic effects. *Liver Cancer* 11:487-496, 2022.
44. Casadei-Gardini A, Rimini M, Kudo M, Shimose S, Tada T, Suda G, Goh MJ, Jefremow A, Scartozzi M, Cabibbo G, Campani C, Tamburini E, Tovoli F, Ueshima K, Aoki T, Iwamoto H, Torimura T, Kumada T, Hiraoka A, Atsukawa M, Itobayashi E, Toyoda H, Sakamoto N, Sho T, Kang W, Siebler J, Neurath MF, Burgio V, Cascinu S: REal life study of LEnVAtiNib therapy for HepAtocellular carcinoma: RELEVANT study. *Liver Cancer* 11:527-539, 2022.
45. Li D, Toh HC, Merle P, Tsuchiya K, Hernandez S, Verret W, Nicholas A, Kudo M: Atezolizumab plus bevacizumab versus sorafenib for unresectable hepatocellular carcinoma: Results from older adults enrolled in the IMbrave150 randomized clinical trial. *Liver Cancer* 11:558-571, 2022.
46. Wu YL, Fulgenzi CAM, D'Alessio A, Cheon J, Nishida N, Saeed A, Wietharn B, Cammarota A, Pressiani T, Personeni N, Pinter M, Scheiner B, Balcar L, Napolitano A, Huang YH, Phen S, Naqash AR, Vivaldi C, Salani F, Masi G, Bettinger D, Vogel A, Schönlein M, von Felden J, Schulze K, Wege H, Galle PR, Kudo M, Rimassa L, Singal AG, Sharma R, Cortellini A, Gaillard VE, Chon HJ, Pinato D, Ang C: Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios as prognostic biomarkers in unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab. *Cancers* 14:5834, 2022. doi: 10.3390/cancers14235834
47. Kudo M, Montal R, Finn R, Castet F, Ueshima K, Nishida N, Haber PK, Hu Y, Chiba Y, Schwartz M, Meyer T, Lencioni R, Llovet JM: Objective response predicts survival in advanced hepatocellular carcinoma treated

- with systemic therapies. *Clin Cancer Res* 28:3443-3451, 2022.
48. Abou-Alfa GK, Lau G, Kudo M, Chan SL, Kelly RK, Furuse J, Sukeepaisarnjaroen W, Kang YK, Dao TV, De Toni EN, Rimassa L, Breder V, Vasilyev A, Heurgue A, Tam VC, Mody K, Thungappa SC, Ostapenko Y, Yau T, Azevedo S, Varela M, Cheng AL, Qin S, Galle PR, Ali S, Gupta C, Makowsky M, Kurland JF, Negro A, Sangro B, fro the HIMALAYA Investigators: Plain language summary of results from the HIMALAYA study: tremelimumab and durvalumab for the treatment of participants with unresectable hepatocellular carcinoma. *Future Oncol* 17, 2023.
 49. Hiraoka A, Kumada T, Tada T, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H, Yasuda S, Toyoda H, Ogawa C, Nishimura T, Hatanaka T, Kakizaki S, Shimada N, Kawata K, Naganuma A, Kosaka H, Ohama H, Tada F, Nouse K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Imai M, Koizumi Y, Nakamura S, Iijima H, Kaibori M, Hiasa Y, Kudo M: Clinical predictor of urinary protein as adverse event associated with atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma. *Oncology* 100:645-654, 2022.
 50. Kudo M, Finn RS, Qin S, Han KH, Ikeda K, Cheng AL, Vogel A, Tovoli F, Ueshima K, Aikata H, López López C, Pracht M, Meng Z, Daniele B, Park JW, Palmer D, Tamai T, Saito K, Dutcus CE, Lencioni R: Overall survival and objective response in advanced unresectable hepatocellular carcinoma: A subanalysis of the REFLECT study. *J Hepatol* 78:133-141, 2023.
 51. Nishida N, Kudo M: Artificial intelligence models for the diagnosis and management of liver diseases. *Ultrasonography* 42:10-19, 2023.
 52. Casadei-Gardini A, Rimini M, Tada T, Suda G, Shimose S, Kudo M, Cheon J, Finkelmeier F, Lim HY, Rimassa L, Presa J, Masi G, Yoo C, Lonardi S, Tovoli F, Kumada T, Sakamoto N, Iwamoto H, Aoki T, Chon HJ, Himmelsbach V, Pressiani T, Montes M, Vivaldi C, Solda C, Piscaglia F, Hiraoka A, Sho T, Niizeki T, Nishida N, Steup C, Iavarone M, Di Costazo G, Marra F, Scartozzi M, Tamburini E, Cabibbo G, Foschi FG, Silletta M, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H, Yasuda S, Toyoda H, Ogawa C, Nishimura T, Hatanaka T, Kakizaki S, Shimada N, Kawata K, Tada F, Ohama H, Nouse K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Imai M, Kosaka H, Naganuma A, Koizumi Y, Nakamura S, Kaibori M, Iijima H, Hiasa Y, Burgio V, Persano M, Della Corte A, Ratti F, De Cobelli F, Aldrighetti L, Cascinu S, Cucchetti A: Atezolizumab plus bevacizumab versus Lenvatinib for unresectable hepatocellular carcinoma: a large real life worldwide population. *Eur J Cancer* 180:9-20, 2023.
 53. Talbot T, D'Alessio A, Pinter M, Balcar L, Scheiner B, Marron TU, Jun T, Dharmapuri S, Ang C, Saeed A, Hildebrand H, Muzaffar M, Fulgenzi CAM, Amara S, Naqash AR, Gampa A, Pillai A, Wang Y, Khan U, Lee PC, Huang YH, Bengsch B, Bettinger D, Abugabal YI, Kaseb A, Pressiani T, Personeni N, Rimassa L, Nishida N, Kudo M, Weinmann A, Galle PR, Muhammed A, Cortellini A, Vogel A, Pinato DJ: Progression patterns and therapeutic sequencing following immune checkpoint

- inhibition for HCC: an international observational study. *Liver Int* 43:695-707, 2023.
54. Thabut D[†], Kudo M[†]: Treatment of portal hypertension in patients with HCC at the era of Baveno VII. *J Hepatol* 78:658-662, 2023. (†Shared 1st authors).
 55. Aramaki O, Takayama T, Matsuyama Y, Kubo S, Kokudo N, Kurosaki M, Murakami T, Shiina S, Kudo M, Sakamoto M, Nakashima O, Fukumoto T, Iijima H, Eguchi S, Soejima Y, Makuuchi M: Reevaluation of Makuuchi's criteria for resecting hepatocellular carcinoma: a Japanese nationwide survey. *Hepatol Res* 53:127-134, 2023.
 56. Kudo M: Prioritized requirements for first-line systemic therapy for hepatocellular carcinoma: Broad benefit with less toxicity. *Liver Cancer* 12:1-6, 2023.
 57. Wu YL, van Hyfte G, Özbek U, Reincke M, Gampa A, Mohamed Y, Nishida N, Wietharn B, Amara S, Lee PC, Scheiner B, Balcar L, Pinter M, Vogel A, Weinmann A, Saeed A, Pillai A, Rimassa L, Naqash AR, Muzaffar M, Huang YH, Kaseb AO, Kudo M, Pinato D, Ang C: Outcomes of beta blocker use in advanced hepatocellular carcinoma treated with immune checkpoint inhibitors. *Front Oncol* 13:1128569, 2023.
 58. Persano M, Rimini M, Tada T, Suda G, Shimose S, Kudo M, Cheon J, Finkelmeier F, Lim HY, Presa J, Masi G, Yoo C, Lonardi S, Pressiani T, Piscaglia F, Kumada T, Rimassa L, Scartozzi M, Cascinu S, Casadei-Gardini A: Identification of Atezolizumab plus Bevacizumab prognostic index via recursive partitioning analysis in HCC: the ABE index. *Anticancer Res* 43:1599-1610, 2023.
 59. Hasegawa K, Takemura N, Yamashita T, Watadani T, Kaibori M, Kubo S, Shimada M, Nagano H, Hatano E, Aikata H, Iijima H, Ueshima K, Ohkawa K, Genda T, Tsuchiya K, Torimura T, Ikeda M, Furuse J, Akahane M, Kobayashi S, Sakurai H, Takeda A, Murakami T, Motosugi U, Matsuyama Y, Kudo M, Tateishi R: Clinical practice guidelines for hepatocellular carcinoma: The Japan Society of Hepatology 2021 version (5th JSH-HCC guidelines). *Hepatol Res* 53:383-390, 2023.
 60. Kato N, Kudo M, Tsuchiya K, Hagihara A, Numata K, Aikata H, Inaba Y, Kondo S, Motomura K, Okano N, Ikeda M, Morimoto M, Kuroda S, Kimura A: Cabozantinib in Japanese patients with advanced hepatocellular carcinoma: final results of a multicenter phase 2 study. *Hepatol Res* 53:409-416, 2023.
 61. Hagiwara S, Nishida N, Kudo M: Advances in immunotherapy for hepatocellular carcinoma. *Cancers* 15:2070, 2023. doi: 10.3390/cancers15072070
 62. Manabe T, Ogawa C, Kakuma K, Nakahara M, Oura K, Tadokoro T, Fujita K, Tani J, Shibato M, Morishita A, Kudo M, Masaki T: Usefulness of the measurement of psoas muscle volume for sarcopenia diagnosis in patients with liver disease. *Diagnostics* 13:1245, 2023. doi: 10.3390/diagnostics13071245
 63. Rimini M, Persano M, Tada T, Suda G, Shimose S, Kudo M, Cheon J, Finkelmeier F, Lim HY, Rimassa L, Presa J, Masi G, Yoo C, Lonardi S, Piscaglia F, Kumada T, Sakamoto N, Iwamoto H, Aoki T, Chon HJ, Himmelsbach V, Pressiani T, Montes M, Vivaldi C, Soldà C, Piscaglia F, Hiraoka A, Sho T, Niizeki T, Nishida N, Steup C, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H, Yasuda S,

Toyoda H, Ogawa C, Nishimura T, Hatanaka T, Kakizaki S, Shimada N, Kawata K, Tada F, Ohama H, Nouse K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Imai M, Kosaka H, Naganuma A, Koizumi Y, Nakamura S, Kaibori M, Iijima H, Hiasa Y, Burgio V, Corte AD, Ratti F, De Cobelli F, Aldrighetti L, Scartozzi M, Casinu S, Casadei-Gardini A: Real world data for atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma: How does adherence to the IMbrave150 trial inclusion criteria impact prognosis? Targeted Oncol 18:221-233, 2023.

2.学会発表

1. Kudo M: Invited Lecture “Multidisciplinary approach for better outcomes in intermediate stage HCC”. APASL-TLW Symposium 6 (Multidisciplinary Approach for Achieving Complete Remission), 31st Conference of the Asian Pacific Association for the Study of the Liver (APASL 2022), April 1, 2022.
2. Kudo M: Luncheon Seminar “ABC Conversion Therapy for HCC”. Roche Luncheon Symposium, 31st Conference of the Asian Pacific Association for the Study of the Liver (APASL 2022), April 2, 2022 (Web).
3. Kudo M: Educational Lecture “Treatment of HCC”. Society of International Digestive Disease (SIDD), Korea, April 16, 2022 (Web).
4. Kudo M: Invited Lecture “ABC Conversion for Intermediate-stage HCC”. Sino-Japan HCC Webinar, China, April 20, 2022 (Web).
5. Kudo M: Invited Lecture “Treatment of Intermediate-stage HCC”. Society of Interventional Radiology (SIR), USA, May 12, 2022 (Web).
6. Kudo M: Invited Lecture “Changing practice of systemic treatment for unresectable HCC in Japan”. APASL STC 2022, June 25, 2022.
7. Kudo M: Invited Lecture “New stage of treatment strategies for HCC -Focusing on intrahepatic tumor”. Hepatocellular Carcinoma Masterclass 2022, Island Shangri-La, Hong Kong, July 23, 2022 (Hybrid).
8. Kudo M: State-of-the Art Lecture “Sequential therapy for HCC after failure of atezolizumab plus bevacizumab”, The 12th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE 2022), Shanghai, China, August 12-14, 2022 (Hybrid)
9. Kudo M: Keynote Lecture “Treatment of Intermediate-stage Hepatocellular Carcinoma”, APASL Oncology 2022 Takamatsu, Takamatsu, Japan, September 1-2, 2022.
10. Kudo M: Invited Lecture “New paradigm of treatment strategy for patients in BCLC B HCC”. The 4th Hubei Provincial Symposium on Precise and Minimally Invasive Comprehensive Diagnosis and Treatment of Hepatobiliary and Pancreatic Tumors, September 24, 2022 (Hybrid).
11. Kudo M: Invited Lecture “New stage of treatment strategies for HCC -Focusing on intrahepatic tumor”. The 6th Northeast Provinces Summit Forum on Tumor Interventional and Minimally Invasive Treatment and the 4th Tumor Minimally Invasive Treatment Forum in Dalian, September 24, 2022 (Hybrid).
12. Kudo M: Luncheon Seminar “Early detection of HCC using HCC biomarkers and GALAD score”. Taiwan Digestive Disease Week 2022 (TDDW 2022), September 24, 2022 (Hybrid).
13. Kudo M: Invited Lecture “Current best option of systemic therapy in HCC”. Taiwan Digestive Disease Week 2022 (TDDW 2022), September 24, 2022 (Hybrid).
14. Kudo M: Invited Lecture “Combination and

- harmonization of systemic therapy and TACE in intermediate stage HCC”. Lenvima-HCC International Exchange Web Seminar, September 27, 2022 (Hybrid).
15. Kudo M: Invited Lecture “Multidisciplinary management of intermediate stage HCC”. Asian Pacific Association for the Study of the Liver 2022 (APASL 2022), October 14, 2022 (Web).
 16. Kudo M: Invited Lecture “New stage of treatment strategies for HCC-focusing on intrahepatic tumors”. The 2022 CJLCA Summit Forum, October 15, 2022 (Web).
 17. Kudo M: Invited Lecture “The trends of development in treatment of advanced liver cancer in Japan”. National Launch Conference, November 13, 2022 (Web).
 18. Kudo M: Invited Lecture “The value and significance of using sonazoid in the whole course of diagnosis and treatment of liver cancer”. Liver Cancer Diagnosis and Treatment Summit Forum, December 24, 2022 (Web).
 19. Kudo M: Invited Lecture “Anti-PD-1/PD-L1 plus anti-VEGF combination immunotherapy for unresectable HCC: Japanese clinical experience”. Cancer Salon: IO+Bev for HCC, December 25, 2022 (Web).
 20. Kudo M, Tsuchiya K, Shao YY, Finn RS, Galle PR, Ducreux M, Cheng AL, Yamashita T, Koga H, Aoki K, Yamada K, Asakawa T, Nakagawa Y, Ikeda M: IMbrave150: Exploratory analysis to examine the association between bevacizumab (bev) ever being skipped and bev never being skipped in patients with unresectable hepatocellular carcinoma (HCC) treated with atezolizumab (atezo) + bev in a global phase 3 study. Gastrointestinal Cancers Symposium (ASCO-GI 2023), San Francisco, USA, January 19-21, 2023.
 21. Kudo M, Aoki T, Ueshima K, Tsuchiya K, Morita M, Hagiwara S, Minami Y, Ida H, Nishida N, Ogawa C, Tomonari T, Nakamura N, Kuroda H, Takebe A, Takeyama Y, Hidaka M, Eguchi S, Chan S, Kurosaki M, Izumi N: Achievement of cancer- and treatment-free status by atezolizumab plus bevacizumab combined with or without curative conversion in patients with transarterial chemoembolization-unsuitable, intermediate-stage hepatocellular carcinoma: A multicenter cohort study. Gastrointestinal Cancers Symposium (ASCO-GI 2023), San Francisco, USA, January 19-21, 2023.

H 知的財産権の出願・登録状況（予定を含む）

- 1.特許取得：なし
- 2.実用新案登録：なし
- 3.その他：なし